This program may be appropriate for adults who have concerns about metabolic health, persistent symptoms that may have multiple contributing factors, or health goals that extend beyond weight loss and are interested in exploring a medically guided approach.

Because symptoms such as fatigue, brain fog, or discomfort can have many possible causes, we don't assume that inflammation, or a particular treatment, is the answer. Your initial consultation allows us to review your health history, symptoms, laboratory findings, previous treatments, and goals before determining whether this program may be appropriate for you.

While both programs may incorporate GLP-1-based medications, they are designed around different treatment goals.

Aurora’s Metabolic Weight Management Program is designed for patients whose primary goal is weight loss and includes medication management, nutrition, exercise, metabolic monitoring, and long-term weight maintenance.

Metabolic Inflammation Management is designed for patients whose primary goal is not significant weight loss. When GLP-1 therapy is appropriate, treatment generally uses a more conservative, low-dose approach focused on metabolic health and the patient's individual response rather than progressing through a traditional weight-loss dosing schedule.

Your initial consultation will help determine which program best aligns with your health needs and goals.

When medication is appropriate, treatment may include low-dose semaglutide or tirzepatide. These medications act on metabolic hormone pathways involved in blood sugar regulation, appetite, digestion, and other aspects of metabolic signaling.

Medication selection is individualized based on your health history, treatment goals, potential risks, tolerance, and response. Not every patient will be an appropriate candidate for GLP-1-based therapy.

Low-dose therapy refers to using a conservative dose of a GLP-1-based medication without automatically progressing through the higher doses commonly used for weight management.

There is no single low dose that's right for everyone. Treatment is individualized based on your health, goals, tolerance, and response. At Aurora, we start conservatively and adjust treatment only when clinically appropriate rather than following a predetermined dose-escalation schedule.

No. GLP-1-based medications are FDA approved for specific conditions such as type 2 diabetes and, for certain medications, chronic weight management and other indications. They are not currently FDA approved specifically for the treatment of chronic inflammation.

Research into the effects of GLP-1 therapies on inflammatory pathways and other areas of health is ongoing. If low-dose GLP-1 therapy is being considered as part of your care, we'll discuss the emerging evidence, potential benefits and risks, limitations, and alternative options so you can make an informed decision about treatment.

You may. GLP-1-based medications can reduce appetite and food intake, so some patients may experience weight loss even when taking lower doses.

However, significant weight loss is not the primary goal of the Metabolic Inflammation Management Program. We'll monitor changes in your weight, appetite, nutrition, and overall health throughout treatment and adjust your plan when appropriate.

If weight loss is one of your primary treatment goals, Aurora's Metabolic Weight Management Program may be a better fit.

Before beginning treatment, we'll identify the specific concerns and health goals we want to monitor. Progress is then evaluated over time based on changes in how you feel, your individual response to treatment, and relevant health or laboratory markers when appropriate.

Because there is no single test that determines whether low-dose GLP-1 therapy is benefiting a particular patient, we'll look at the overall picture rather than relying on one symptom or lab value. If you're not experiencing meaningful benefit, we'll reassess whether continuing or adjusting treatment makes sense.

There is no predetermined treatment duration. How long you continue therapy will depend on your individual response, treatment goals, tolerance, and whether you are experiencing meaningful benefit.

We'll periodically reassess your progress and discuss whether it makes sense to continue, adjust, reduce, or discontinue treatment. The goal is to use medication only as long as it remains appropriate and beneficial for your individual needs.

The most common side effects of GLP-1-based medications are gastrointestinal and may include nausea, constipation, diarrhea, abdominal discomfort, decreased appetite, or feeling full more quickly.

Although a lower-dose approach may help some patients tolerate treatment, side effects can still occur. We'll review potential risks before treatment, provide guidance on managing common side effects, and monitor your response throughout your care.

If you experience side effects, your treatment plan can be adjusted based on their severity and your individual response.

Laboratory testing may be recommended before starting treatment to better understand your metabolic health, identify potential concerns, and establish relevant baseline markers.

The specific tests recommended will depend on your health history, symptoms, medications, previous laboratory results, and treatment plan. Follow-up testing may also be recommended during treatment to monitor relevant health markers and guide ongoing care.

Any recommended testing and associated costs will be discussed with you before labs are ordered.